Walboomers, JM, et al.
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Journal of Pathology
1999; 189: 12–19.
Hantz, S, Alain, S, Denis, F. Anti-papillomavirus vaccines and prevention of cervical cancer: progress and prospects [in French]. Presse Medicale
2005; 34: 745–753.
Duport. Epidemiological data on cervical cancer – 2008 update. In Sanitaire INdV. INVS, 2008, pp. 1–31.
Eluf-Neto, J, Nascimento, CM. Cervical cancer in Latin America. Seminars in Oncology
2001; 28: 188–197.
Roue, T, et al.
Cervical cancer incidence in French Guiana: South American. International Journal of Gynecological Cancer
2012; 22: 850–853.
Douine, M, et al.
Survival of patients with invasive cervical cancer in French Guiana, 2003–2008. International Journal of Gynaecology and Obstetrics
2014; 125: 166–167.
Arrossi, S, Sankaranarayanan, R, Parkin, DM. Incidence and mortality of cervical cancer in Latin America. Salud Publica de Mexico
2003; 45 (Suppl. 3): S306–314.
van Melle, A, et al.
Knowledge, attitudes, behaviors, and practices differences regarding HIV in populations living along the Maroni river: particularities of operational interest for Amerindian and Maroon populations. AIDS Care
2015; 27: 1112–1117.
Nacher, M, et al.
What is driving the HIV epidemic in French Guiana?
International Journal of STD and AIDS
2010; 21: 359–361.
Franceschi, S, et al.
Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. International Journal of Cancer
2006; 119: 2677–2684.
Forman, D, et al.
Global burden of human papillomavirus and related diseases. Vaccine
2012; 30 (Suppl. 5): F12–23.
Lazcano-Ponce, E, et al.
Epidemiology of HPV infection among Mexican women with normal cervical cytology. International Journal of Cancer
2001; 91: 412–420.
Molano, M, et al.
Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. American Journal of Epidemiology
2003; 158: 486–494.
Lazcano-Ponce, E, et al.
High prevalence of human papillomavirus infection in Mexican males: comparative study of penile-urethral swabs and urine samples. Sexually Transmitted Diseases
2001; 28: 277–280.
Toliman, P, et al.
Field evaluation of the Xpert® HPV Point of Care Test for the detection of human papillomavirus infection using self-collected vaginal and clinician-collected cervical specimens. Journal of Clinical Microbiology
2016; 54: 1734–1737.
Lynge, E, et al.
What happens when organization of cervical cancer screening is delayed or stopped?
Journal of Medical Screening
2006; 13: 41–46.
Sankaranarayanan, R, et al.
HPV screening for cervical cancer in rural India. New England Journal of Medicine
2009; 360: 1385–1394.
Londesborough, P, et al.
Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. International Journal of Cancer
1996; 69: 364–368.
Riethmuller, D, et al.
Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France. BMC Public Health
2015; 15: 453.
Roué, T, Nacher, M. Epidemiology of cancer in the tropical areas. In: Tropical Hemato-Oncology. Cham, Switzerland: Springer International Publishing, 2015, pp. 17–23.
Broberg, G, et al.
Increasing participation in cervical cancer screening: offering a HPV self-test to long-term non-attendees as part of RACOMIP, a Swedish randomized controlled trial. International Journal of Cancer
2014; 134: 2223–2230.
Wright, TC, et al.
Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecologic Oncology
2015; 136: 189–197.